Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders	Erdheim-Chester disease, Hemic and Lymphatic Diseases, Histiocytosis, Langerhans-Cell, Neoplasms by Histologic Type, Skin and Connective Tissue Diseases, histiocytic sarcoma, histiocytosis, interstitial lung disease, juvenile xanthogranuloma, lung disorder, lymphatic system disorder, malignant histiocytosis, neoplasm, non-Langerhans cell histiocytosis, respiratory system disorder, sinus histiocytosis with massive lymphadenopathy, skin disorder	Recruiting	Phase 2	2025-09-18		NCT04079179

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Baylor College of Medicine	267
Carl Allen	1
Genentech, Inc.	221
North American Consortium for Histiocytosis	4

12 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Arkansas Children's Hospital	Little Rock	United States	82
Children'S Hospital of Orange County	Orange	United States	128
Children's Medical Center- UTSW	Dallas	United States	1
Children's National Hospital	Washington D.C.	United States	100
Dana Farber Cancer Institute, Boston Children's	Boston	United States	1
John Hopkins University School of Medicine	Baltimore	United States	6
Memorial Sloan Kettering Cancer Center	New York	United States	1000
NACHO Consortium	Memphis	United States	1
Phoenix Children's Hospital	Phoenix	United States	95
Texas Children's Hospital	Houston	United States	187
UCSF Benioff Children's Hospital	San Francisco	United States	13
University of Wisconsin-American Family Children's Hospital	Madison	United States	1